Skip to main content

Table 2 Unitary costs (€, 2016) and parameters used in the model

From: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

Parameter

Resource consumption

Source

Prophylaxis costs

 Pharmaceutical cost

  Palivizumab (Synagis ®) 50 mg per vial (€)

511.66

[34]

  Palivizumab (Synagis ®) 100 mg per vial (€)

849.64

[34]

  Average pharmaceutical cost (EFP/mg) (€)

7.30

 

  Average dose (mg/preterm infant) per injection

65.34

 

 Administration cost

  Average number of injections

3.88

[28]

  Administration cost per injection (€)-

9.58

[36]

 Hospitalization cost

  Daily cost in paediatric ward (€)

641.06

[36]

  Hospital length of stay (days)

6

Post-hoc analysis FLIP II study [14]

 ICU related costs

  Daily costs in ICU paediatric ward (€)

2,286.28

[36]

  ICU length of stay (days) cost per visit

5

[14]

 Emergency visit prior hospitalization cost

  Daily cost of emergency ward (€)

103.95

[36]

 Annual recurrent wheezing management costs

  Direct cost (€)

749.57

[37]

  Indirect cost (€)

498.62

[37]

  1. EFP: ex-factory price; ICU: intensive care unit